Industry status: Lianyungang is the country's largest export base of preparations to the United States, an important national production base for innovative drugs and modern Chinese medicine, and a national demonstration base for new industrialized industries. The total output value of the pharmaceutical industry is nearly 100 billion. With Hengrui Medicine, Chia Tai Tianqing, Hansoh Pharmaceutical, Kangyuan Pharmaceutical as the main enterprises; with key enterprises such as Nuotai Pharmaceutical, Deyuan Pharmaceutical, Suyun Medical, Youyuan Pharmaceutical, Fubang Pharmaceutical, etc., pharmaceutical research and development There are more than 260 production and related supporting enterprises.
Industrial planning: Focusing on building a domestic first-class and world-renowned "China Pharmaceutical Port", vigorously develop the industrial chain of chemical drugs, biological drugs, traditional Chinese medicine and new medical devices, with an output value exceeding 100 billion yuan by 2023 and 136 billion yuan by 2025 . Promote the integrated development of raw materials and preparations, promote the construction of national raw material drug production bases with high standards, and gradually establish a full industrial chain for the production of chemical drug preparations; accelerate the deployment of biological drugs in advantageous fields such as malignant tumors and cardiovascular and cerebrovascular diseases, and promote the industry of biological drug projects under development. to create a whole industrial chain of biological medicines; guide the standardized planting and breeding of Chinese medicinal materials, explore a new mode of cooperation between Chinese medicine enterprises and Chinese medicinal materials production areas, and optimize the whole industrial chain of Chinese patent medicine production; promote the advantageous industries such as disinfection and sterilization equipment to strengthen technical research and break through high-end The localization of equipment and core components is the bottleneck, and the medical device industry chain has jumped to high-end.
Innovation platform: Hengrui Pharmaceutical Nationally Recognized Enterprise Technology Center, Hansoh Pharmaceutical Nationally Recognized Enterprise Technology Center, Kangyuan Pharmaceutical Nationally Recognized Enterprise Technology Center, Chia Tai Tianqing Pharmaceutical Nationally Recognized Enterprise Technology Center, Hansoh Pharmaceutical Long-acting Peptide National and Local Joint Engineering Research Center for Biological Drug Development, Kangyuan Pharmaceutical National and Local Joint Engineering Research Center for Intelligent Manufacturing of Chinese Patent Medicine, Hengrui Medicine National and Local Joint Engineering Research Center for Anti-tumor Targeted Drugs, Hengrui Medicine National Targeted Drug Engineering Technology Research A number of third-party services and public platforms such as the Center, Jiangsu Original Chemical Drug Innovation Center, Green Pharmaceutical Technology Research Institute of Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Hangzhou Heze Pharmaceutical CRO and MAH Transformation Platform. In 2019, China Pharmaceutical Port newly undertook 27 major scientific and technological projects of "Major New Drug Creation", ranking first in the country; 5 Class 1 new drugs were approved, accounting for 62.5% of the province and 45.5% of the country. At present, the research and development of new drugs in our city has entered the harvest period, creating the "Lianyungang phenomenon" that the domestic pharmaceutical industry has new generic drugs on the market every year, and one category of new drugs is approved every to three years.
Industrial talents: Jiangsu Ocean University, Kangda College of Nanjing Medical University and other pharmaceutical-related colleges and universities reserve nearly 30,000 students with a college degree or above in medicine-related majors, and can carry out "order-based" training according to the needs of enterprises. There are more than 20,000 people with a bachelor's degree or above in pharmaceutical production enterprises. In the three years from 2018 to 2020, there will be 1,088 high-end talents in the new pharmaceutical industry awarded by the municipal government (basic conditions: the annual salary exceeds 200,000 and the core personnel of the core department of the pharmaceutical enterprise) , to meet the high-quality labor needs of enterprises.
Industrial capital: Establish different types of professional sub-funds to attract and leverage higher-level financial funds, social capital and financial capital to participate in industrial investment in our city. There are several municipal-level state-owned investment platforms such as Lianyungang Industrial Investment Group Co., Ltd. and Lianyungang Financial Holding Group Co., Ltd. (responsible for guiding and leveraging all kinds of financial and social capital to gather in key parks, key industries and key enterprises in our city). At present, more than ten funds have been established or participated in the establishment of pharmaceutical industry funds, major investment funds, mergers and acquisitions funds, etc., and the scale of the parent fund has exceeded 15 billion yuan (142+15).
Industrial projects: Hansoh Biopharmaceuticals, Runzhong Bioengineering Drug R&D and Production Base, Hengrui Biopharmaceutical Industrial Park, Deyuan API and Preparation Production Base, China Pharmaceutical Port International Pharmaceutical Innovation Industrial Park, Lianyu Medical Device R&D and Production Phase II projects etc.
